LeadStory

CNBC

Synchron CEO explains the science behind their brain chip implants

CNBC · Just In
CNBC
CNBC
Just In

Synchron CEO Tom Oxley tells CNBC’s Squawk Box Asia that the company’s brain chip implant is designed to treat motor impairments now, with plans to address mild cognitive decline in the future. He also details how the implant is embedded in patients.

Breakdown
  • First-generation Synchron brain chip targets restoring motor control for people with paralysis or motor impairment.
  • The device is priced between $50,000 and $100,000, with significant market potential for millions globally. 28s
  • Future technology aims to help hundreds of millions with cognitive decline, including dementia. 1m 2s
  • China is rapidly developing BCI technology, with government-led initiatives and several companies active, though still about five years behind the U.S. 1m 54s
  • Synchron's implant is delivered via blood vessels through the neck, inspired by cardiology procedures, offering a minimally invasive alternative to open-brain surgery. 2m 56s
Companies & StartupsTechnologyMedical Research